Biogen Upgrade - Neuroscience Diversification and Cash Flow Make the Case for a Strategic Long
Biogen ($BIIB) is trading at $235.36 with a $34.8B market cap, strong free cash flow and a revitalized earnings cadence. The bull case now extends beyond Alzheimer’s: existing neurology franchises, recurring royalties, and RNA/oligo tailwinds give the company multiple durable growth vectors. We upgrade to a tactical long with defined entry, stop an…